Bristol Myers Squibb Co
CELG.RI- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000014272
In the last 90 days, Bristol Myers Squibb Co insiders filed 0 open-market purchases and 2 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesBMY
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Bristol Myers Squibb Co insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $437.2K in total
- Insiders trading
- 2
- Net value
- −$437.2K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Bristol Myers Squibb Co, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | 18,748 | Sep 10, 2026 | 3 |
| Short Bartie Wendy | EVP, Corporate Affairs | 12,684 | Sep 3, 2026 | 3 |
| Holzer Phil M | SVP and Controller | 16,862 | Aug 26, 2026 | 2 |
| Gallman Cari | EVP, General Counsel | 13,649 | Aug 4, 2026 | 3 |
| Yale Phyllis R | Director | – | Jul 2, 2026 | 5 |
| Samuels Theodore R. II | Director | 35,500 | Jul 2, 2026 | 5 |
| Rice Derica W | Director | – | Jul 2, 2026 | 5 |
| McMullen Michael R. | Director | – | Jul 2, 2026 | 5 |
| Arduini Peter J | Director | – | Jul 2, 2026 | 5 |
| Haller Julia A | Director | 34,079 | Jun 16, 2026 | 2 |
| Lenkowsky Adam | EVP, Chief Commercial Officer | 19,706 | May 5, 2026 | 3 |
| Elkins David V | EVP, Chief Financial Officer | 159,248 | Apr 2, 2026 | 2 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops | 25,888 | Apr 2, 2026 | 3 |
| Boerner Christopher S. | Chief Executive Officer | 21,451 | Mar 12, 2026 | 2 |
| Hickey Benjamin | President, RayzeBio Org. | 16,672 | Mar 12, 2026 | 3 |
| Plenge Robert M | EVP, Chief Research Officer | 21,528 | Mar 12, 2026 | 1 |
| Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | 30,361 | Mar 12, 2026 | 3 |
| Poole Ahn Amanda | EVP, Chief People Officer | 7,094 | Mar 12, 2026 | 1 |
| Hoch Lynelle | President, Cell Therapy Org. | 8,210 | Mar 12, 2026 | 1 |
| Shibutani Hiroshi Chris | EVP, Chief Strategy Officer | – | Mar 12, 2026 | 1 |
| Price Paula A | Director | – | Feb 3, 2026 | 1 |
| Vousden Karen H | Director | – | Feb 3, 2026 | 1 |
| Hidalgo Medina Manuel | Director | – | Feb 3, 2026 | 1 |
| Bhatt Deepak | Director | – | Feb 3, 2026 | 1 |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 83,513 | Apr 29, 2025 | 0 |
| Leung Sandra | EVP, General Counsel | 364,296 | Mar 12, 2025 | 0 |
| Storch Gerald L | Director | – | Apr 2, 2024 | 0 |
| Caforio Giovanni | Executive Chair of the Board | 432,266 | Mar 12, 2024 | 0 |
| Powell Ann | EVP, Chief Human Resources | 27,868 | Aug 28, 2023 | 0 |
| Weese Michelle | EVP, Corporate Affairs | 3,453 | Jul 5, 2023 | 0 |
| Vessey Rupert | EVP & President, Research | 47,751 | May 4, 2023 | 0 |
| Greenlees Sharon | SVP & Controller | 609 | May 3, 2023 | 0 |
| Mily Elizabeth | EVP, Strategy & BD | 34,734 | Apr 4, 2023 | 0 |
| Santiago Karen Murphy | SVP & Controller | 16,704 | Mar 16, 2022 | 0 |
| von Autenried Paul | EVP, Chief Information Officer | 63,536Indirect | Nov 24, 2021 | 0 |
| Dubow Adam | SVP,ChiefCompliance&EthicsOff. | 13,777 | Aug 3, 2021 | 0 |
| Bonney Michael W | Director | – | Jul 1, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)4:37 PM ET | Sep 9 | 1 day | Massacesi CristianEVP,Chief Med Offr,Head of Dev | SSaleCommon Stock, $0.10 par value | −6.25K | $64.57 | −$403.5K | −25.0%18.7K after | |
| Aug 26, 2026 (view filing)4:17 PM ET | Aug 25 | 1 day | Holzer Phil MSVP and Controller | SSaleCommon Stock, $0.10 par value | −500 | $67.50 | −$33.8K | −2.9%16.9K after | |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Elkins David VEVP, Chief Financial Officer | SSaleCommon Stock, $0.10 par value | −30.0K | $61.67 | −$1.85M | −15.9%159.2K after | 2 lots |
| Sep 3, 2025 (view filing) | Sep 2 | 1 day | Elkins David VEVP, Chief Financial Officer | SSaleCommon Stock, $0.10 par value | −56.0K | $47.33 | −$2.65M | −25.1%167.4K after | |
| Aug 5, 2025 (view filing) | Aug 2 | 3 days | Short Bartie WendyEVP, Corporate Affairs | SSaleCommon Stock, $0.10 par value | −378 | $44.23 | −$16.7K | −6.9%5.07K after | |
| May 13, 2025 (view filing) | May 9 | 4 days | Hickey BenjaminPresident, RayzeBio Org. | SSaleCommon Stock, $0.10 par value | −97.39 | $38.01 | −$3.70K | −100.0%0 after | |
| Apr 29, 2025 (view filing) | Apr 25 | 4 days | Hirawat SamitEVP,Chief Med.Offr.,Drug Dev. | PPurchaseCommon Stock, $0.10 par value | +4.25K | $47.58 | +$202.2K | +5.4%83.5K after | |
| Feb 21, 2025 (view filing) | Feb 20 | 1 day | Boerner Christopher S.Chief Executive Officer | PPurchaseCommon Stock, $0.10 par value | +2.00K | $55.05 | +$110.1K | +1.9%104.6K after | |
| Feb 19, 2025 (view filing) | Feb 14 | 5 days | Hirawat SamitEVP,Chief Med.Offr.,Drug Dev. | PPurchaseCommon Stock, $0.10 par value | +1.82K | $54.84 | +$100.0K | +2.9%63.9K after | |
| Nov 5, 2024 (view filing) | Nov 4 | 1 day | Holzer Phil MSVP and Controller | SSaleCommon Stock, $0.10 par value | −700 | $55.62 | −$38.9K | −5.6%11.8K after | |
| Nov 5, 2024 (view filing) | Nov 1 | 4 days | Hirawat SamitEVP,Chief Med.Offr.,Drug Dev. | PPurchaseCommon Stock, $0.10 par value | +1.83K | $54.68 | +$100.1K | +3.0%62.1K after | |
| Dec 7, 2023 (view filing) | Dec 5 | 2 days | Boerner Christopher S.Chief Executive Officer | PPurchaseCommon Stock, $0.10 par value | +2.00K | $49.78 | +$99.6K | +2.5%82.7K after | |
| Nov 30, 2023 (view filing) | Nov 28 | 2 days | Boerner Christopher S.Chief Executive Officer | PPurchaseCommon Stock, $0.10 par value | +3.07K | $48.86 | +$150.0K | +4.0%79.4K after | |
| Nov 21, 2023 (view filing) | Nov 20 | 1 day | Samuels Theodore R. IIDirector | PPurchaseCommon Stock, $0.10 par value | +8.50K | $49.81 | +$423.4K | +31.5%35.5K after | |
| Aug 28, 2023 (view filing) | Aug 24 | 4 days | Powell AnnEVP, Chief Human Resources | SSaleCommon Stock, $0.10 par value | −18.0K | $61.25 | −$1.10M | −39.2%27.9K after | |
| Aug 7, 2023 (view filing) | Aug 3 | 4 days | Plenge Robert MEVP, Chief Research Officer | SSaleCommon Stock, $0.10 par value | −732 | $61.14 | −$44.8K | −10.0%6.58K after | |
| May 4, 2023 (view filing) | May 3 | 1 day | Vessey RupertEVP & President, Research | SSaleCommon Stock, $0.10 par value | −50.4K | $67.06 | −$3.38M | −51.3%47.8K after | |
| Feb 8, 2023 (view filing) | Feb 6 | 2 days | Caforio GiovanniBoard Chair and CEO | SSaleCommon Stock, $0.10 par value | −240.0K | $74.65 | −$17.9M | −50.4%236.1K after | |
| Feb 8, 2023 (view filing) | Feb 6 | 2 days | Powell AnnEVP, Chief Human Resources | SSaleCommon Stock, $0.10 par value | −11.2K | $74.69 | −$835.3K | −32.7%23.0K after | |
| Nov 14, 2022 (view filing) | Nov 9 | 5 days | Powell AnnEVP, Chief Human Resources | SSaleCommon Stock, $0.10 par value | −16.3K | $80.45 | −$1.31M | −32.2%34.2K after | |
| Nov 9, 2022 (view filing) | Nov 7 | 2 days | Vessey RupertEVP, Research & Early Dev. | SSaleCommon Stock, $0.10 par value | −45.9K | $78.88 | −$3.62M | −44.6%57.1K after | |
| Sep 22, 2022 (view filing) | Sep 20 | 2 days | Caforio GiovanniBoard Chair and CEO | SSaleCommon Stock, $0.10 par value | −25.0K | $69.71 | −$1.74M | −5.0%476.1K after | |
| Sep 16, 2022 (view filing) | Sep 15 | 1 day | Caforio GiovanniBoard Chair and CEO | SSaleCommon Stock, $0.10 par value | −50.0K | $71.84 | −$3.59M | −9.1%501.1K after | |
| Sep 15, 2022 (view filing) | Sep 13 | 2 days | Elkins David VEVP, Chief Financial Officer | SSaleCommon Stock, $0.10 par value | −134.0K | $71.30 | −$9.55M | −52.8%119.8K after | 2 lots |
| Sep 15, 2022 (view filing) | Sep 14 | 1 day | Powell AnnEVP, Chief Human Resources | SSaleCommon Stock, $0.10 par value | −25.0K | $70.75 | −$1.77M | −33.1%50.5K after | |
| Jun 14, 2022 (view filing) | Jun 13 | 1 day | Caforio GiovanniBoard Chair and CEO | SSaleCommon Stock, $0.10 par value | −30.0K | $74.04 | −$2.22M | −5.2%551.1K after | |
| Jun 7, 2022 (view filing) | Jun 6 | 1 day | Leung SandraEVP, General Counsel | SSaleCommon Stock, $0.10 par value | −65.0K | $74.89 | −$4.87M | −17.4%308.6K after | |
| Mar 23, 2022 (view filing) | Mar 21 | 2 days | Caforio GiovanniBoard Chair and CEO | SSaleCommon Stock, $0.10 par value | −25.0K | $71.52 | −$1.79M | −4.1%581.5K after | |
| Mar 18, 2022 (view filing) | Mar 16 | 2 days | Vessey RupertEVP, Research & Early Dev. | SSaleCommon Stock, $0.10 par value | −74.6K | $69.25 | −$5.16M | −59.7%50.4K after | 2 lots |
| Mar 16, 2022 (view filing) | Mar 14 | 2 days | Santiago Karen MurphySVP & Controller | SSaleCommon Stock, $0.10 par value | −6.58K | $69.20 | −$455.1K | −28.3%16.7K after | |
| Mar 16, 2022 (view filing) | Mar 14 | 2 days | Boerner Christopher S.EVP, Chief Commercial Officer | SSaleCommon Stock, $0.10 par value | −29.5K | $69.20 | −$2.04M | −41.3%42.0K after | |
| Feb 28, 2022 (view filing) | Feb 24 | 4 days | Caforio GiovanniBoard Chair and CEO | SSaleCommon Stock, $0.10 par value | −30.0K | $67.00 | −$2.01M | −6.2%453.5K after | |
| Dec 17, 2021 (view filing) | Dec 16 | 1 day | Vessey RupertEVP, Research & Early Dev. | SSaleCommon Stock, $0.10 par value | −19.3K | $61.99 | −$1.20M | −37.6%32.0K after | 2 lots |
| Nov 24, 2021 (view filing) | Nov 22-24 | 2 days | von Autenried PaulEVP, Chief Information Officer | SSaleCommon Stock, $0.10 par value | −51.1K | $57.18 | −$2.92M | −44.6%63.5K after | 3 lots |
| Sep 22, 2021 (view filing) | Sep 20 | 2 days | Caforio GiovanniBoard Chair and CEO | SSaleCommon Stock, $0.10 par value | −25.0K | $60.64 | −$1.52M | −4.9%484.0K after | |
| Aug 16, 2021 (view filing) | Aug 12 | 4 days | Elkins David VEVP, Chief Financial Officer | SSaleCommon Stock, $0.10 par value | −99.7K | $66.95 | −$6.67M | −55.5%80.0K after | 2 lots |
| Aug 4, 2021 (view filing) | Aug 2 | 2 days | Caforio GiovanniChairman and CEO | SSaleCommon Stock, $0.10 par value | −20.0K | $68.58 | −$1.37M | −3.8%509.0K after | |
| Aug 4, 2021 (view filing) | Aug 3 | 1 day | Powell AnnEVP, Chief Human Resources | SSaleCommon Stock, $0.10 par value | −23.3K | $68.57 | −$1.60M | −32.8%47.6K after | |
| Aug 3, 2021 (view filing) | Jul 30 | 4 days | Dubow AdamSVP,ChiefCompliance&EthicsOff. | SSaleCommon Stock, $0.10 par value | −2.47K | $67.90 | −$167.4K | −15.2%13.8K after | |
| Aug 3, 2021 (view filing) | Jul 30 | 4 days | Leung SandraEVP, General Counsel | SSaleCommon Stock, $0.10 par value | −29.4K | $68.04 | −$2.00M | −8.0%340.0K after | |
| Aug 3, 2021 (view filing) | Jul 30 | 4 days | Vessey RupertEVP, Research & Early Dev. | SSaleCommon Stock, $0.10 par value | −158.4K | $68.07 | −$10.8M | −77.1%47.0K after | 2 lots |
| Aug 3, 2021 (view filing) | Jul 30 | 4 days | von Autenried PaulEVP, Chief Information Officer | SSaleCommon Stock, $0.10 par value | −25.0K | $68.06 | −$1.70M | −17.9%114.7K after |